Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Small blocks on bid and ask. We're all in and like what we hold. We need new eyes & buyers to move bigly.
A slice of $3.8 billion will make this very golden.
Why a PPE shortage still plagues America
PUBLISHED SAT, AUG 22 202010:00 AM EDT Dan Cohen, CEO of 3DBio Therapeutics
Six months into the Covid-19 crisis, there is still a dire shortage of personal protective equipment for our health-care workers, says Dan Cohen, CEO of 3DBio Therapeutics.
Six months into the Covid-19 crisis, there is still a dire shortage of personal protective equipment (PPE) for our health-care workers, particularly those on the front lines of the coronavirus pandemic. Doctors and nurses are still reusing single use N-95s and experiencing shortages of face shields and gloves. How did this happen in a country ranked No. 1 in pandemic preparedness by the WHO, one which comprises 40% of total global pharma spending, and represents 24% of global economic output?
At the start of the crisis, the federal government’s Strategic National Stockpile included 12 million N95 masks and 30 million surgical masks, about 1% of the 3.5 billion required in the U.S. in the first year of the pandemic.
The reason for the shortage was clear then: a reliance on outsourcing PPE manufacturing to China. The White House had to order 500 million respirators from China, and received a delivery timeline of 18 months or more. But despite the efforts of major U.S. companies and innovative entrants shifting to produce PPE, why has this shortage persisted?
Because there are already signs that PPE manufacturers are ramping down production to avoid the risk of holding surplus inventory. With the prospect of another wave of Covid cases in the fall, this could lead to additional shortages.
PPE costs will top $3.8 billion in second half of 2020
As the co-founder and CEO of 3DBio Therapeutics, which 3-D bioprints medical implants end-to-end in New York City, when Covid-19 began I wanted to help. I witnessed firsthand the PPE shortage doctors, nurses and other health-care workers had to deal with at the height of the crisis that endangered their safety. In response, we pivoted and worked nights and weekends to build a Powered Air-Purifying Respirator (PAPR), under the moniker American PAPR. PAPRs, crucial PPE for medical professionals treating infectious disease, consist of a hooded plastic mask and breathing tube that block 99.97% of small particles. PAPRs were most famously worn by the doctors in the movie “Outbreak.”
What is hampering PPE supplies We were honored to be one of only a handful of manufacturers (alongside Ford) to receive rapid regulatory approval from the National Institute for Occupational Safety and Health (NIOSH). But the main obstacles we have faced in getting PPE to medical professionals are the three same core issues that have stymied American ingenuity and productivity during this crisis.
First, budget shortfalls have been an issue for hospitals throughout the pandemic, because critical care and inpatient services are their least profitable areas. Hospitals nationwide lost over $161 billion due to canceled procedures from March to June 2020, while uninsured visits rose 114%. This has resulted in limited budgets for PPE.
Second, unpredictability in demand creates further risk to producing PPE. Existing players or new entrants like us need to create capacity by investing to expand production. Yet in the midst of a crisis, demand is hard to predict, given budget challenges and high degrees of local volatility as the curve flattens or regions spike. In a chaotic market, there is substantial risk to your primary business if your investment in production mistimes demand.
Lastly, concerns about fraud tie hospitals to familiar manufacturers. Regulatory authorities, including the FDA and NIOSH, have been heroic in shortening timelines to get safe PPE into the hands of health-care workers. But inundated by a barrage of unreliable PPE imported from China, institutions cannot easily discern quality products from counterfeit. Unpredictable pandemic-led demand surges require nimble and local U.S. manufacturing, but hospitals face liabilities in working with new entrants.
As a nation we can try Band-Aid solutions, but I propose a simple concept to meet this urgent need and ensure our pandemic readiness for decades, while also creating jobs for our faltering economy: fund a dynamic ecosystem of U.S.-based medical production, a Manufacturing Reserve Corps.
In the next health-care emergency, imagine a network of thousands of trusted, U.S.-based, pre-approved digital manufacturing companies, standing by ready to kick into gear. Digital manufacturers use computer software to coordinate production, and can flexibly produce a broad range of medical products with minimal switching costs. These companies could build out the Strategic National Stockpile, just as aerospace & defense companies do with government contracts. This could be a modern-day equivalent of the War Production Board during World War II, converting factories from peacetime production to war needs.
Building this network of U.S.-based manufacturing firms would have a clear economic and societal return. Though manufacturing makes up only 9% of U.S. employment, it drives 35% of productivity growth, 60% of exports, and 70% of private-sector R&D, according to the McKinsey Global Institute.
A Reserve Corps could focus on traditional industrial manufacturing during peacetime, and would create thousands of U.S. jobs in industrial centers and small towns across the country.
Covid-19 is the greatest crisis of our lifetime. It has elucidated that flexible U.S.-based medical manufacturing is now an economic security and public health imperative. We urgently need federal incentives to build it.
https://www.cnbc.com/2020/08/22/coronavirus-why-a-ppe-shortage-still-plagues-the-us.html
AC/DC.
No problem. Good luck to you.
Whatever, they'll spend far more than that in attorneys fees fighting over it. Just look at the number of court docs going through. There are teams of lawjockey's working to retain the IP. That tells me far more that what you posted.
It's all up to the judge but he's has already made a decision that benefits everyone. He already seen the claims made by all creditor parties before making the initial call. Can't see it being changed.
Thank you fojcol, We sure see it the same. It may take a bit longer but the value sure seems to be there.
Thank you decogold.
Based on the amount of legal activity the past weeks, all based on securing BRTXQ's Intellectual Property supports exactly what many here have been saying, it's worth a huge amount.
BioRetorative Theraphies Inc. vs Desmarais, Tuxis et al
Disclaimer: First off I'm a dumba** investor, not an attorney so this is my opinion for what its worth, as to what is going on with BRXTQ vs Desmarais.
After reading a few court docs, Desmarais, et al loaned monies on multiple occasions to BRTXQ. In 2016 on loans, BRXT, (at the time), used their intellectual property as collateral in obtaining a loans. Demarais el al's contention is they are therefore owed the IP, before any other entity gets any satisfaction from BRTXQ. Allowing this action would cause BRTXQ to go Chapter 7 bankruptcy and the only entity getting any type of return would be Desmarais et al, a minority debtor. BY THE WAY, THE CLAIM WAS FILED MORE THAN 3 MONTHS AFTER BRTXQ'S BANKRUPTCY WAS FILED. (March 20, 2020 vs July 1, 2020 This should provide protection under bankruptcy law.
BRTXQ via their attorneys contend that the whole issue is non-statutory and is a common law matter. This simply means, this ruling would be based on what previous courts outcomes had been, historical precedent. Obviously, they wouldn't be making this contention if prior rulings were contrary to their claim.
The Judge's has already ruled in favor of BRTXQ going the Chapter 11 route where each party and the shareholders are made as whole as possible. Changing his decision and doing a Chapter 7 would leave the largest creditor, Auctus and most of the almost $15 million due creditors unpaid and the stockholders shares worth nothing.
So, the effort from BRXTQ's legal team is to do exactly what the Reorganizaton Plan states and treat Demarais et al the same as every other creditor. All would be made whole and the shareholders retain the value in their shares.
I can't see the Judge changing a ruling just to favor one creditor and shutting out the rest with nothing.
JMHO Airdale1
Really, the release of the lean isn't straight forward? Which lien are you referencing?
The lien securing the July 2017 Desmarais Note was perfected within one (1) year of the Petition Date and, as a result, it appears that such lien is avoidable under Chapter 5 of the Bankruptcy Code.
Where are multiples of 400M shares promised in the plan?
Why not show the language you are referencing to the board?
A reverse split is not in the Reorganization plan BioRestorative and AUCTUS submitted and the Judge approved and you know that.
One more reason that this settlement will go forth. As shown in POST #12583, each Class 3 member, (this includes Desmeris and Auctus), who is owed monies by the Debtor in Possession under the Plan of Reorganization will get:
a) Common Stock for their allowed claims, or
b) if they provide at least 75% of their claim in financing, they get a secured convertible note.
Those are extremely fair terms for companies that would receive less than .08 per dollar of monies owed them if they turn down the Reorg Plan.
The Plan of Reorganization will go through unless the entity is entirely brainless, IMO. See what they receive if they turn down the Reorg, below.
Statement of Reorganization
Page 7:
Unless there is acceptance of the Plan by all members of an impaired Class, the Bankruptcy Court must also determine that Class members will receive under the Plan property of a value, as of the Effective Date, that is not less than the amount that such Class members would receive or retain if the Debtors were liquidated under Chapter 7 of the Bankruptcy Code on the Effective Date.[/i]
I see nothing regarding an extension for the case. Please provide a link.
Here's why I don't think there will be a battle and the current plan will be accepted. AUCTUS is the largest creditor, by far.
The Disclosure Agreement states that all creditors will be made 100% whole:
II. SUMMARY OF THE PLAN
The Plan contemplates that new capital will be raised that will provide for the payment of Allowed Claims under the Plan and the funding of the Reorganized Debtor’s continued operations, including clinical trials and other steps necessary to continue the development of the Debtor’s technology and intellectual property. The Plan provides for the satisfaction in full of all Allowed Secured Claims, Administrative Claims, Priority Claims and Priority Tax Claims, unless the holders of such Claims agree to different treatment. The holders of Allowed General Unsecured Claims will receive, at their election, either (a) common stock in the Reorganized Debtor in exchange for their Allowed Claims, or (b) if they choose to provide financing to the Reorganized Debtor in an amount of not less than seventy-five percent (75%) of their respective Allowed Claims, a Convertible Plan Note for the amount of their respective Allowed Claims and a Secured Convertible Plan Note for the amount of financing they provide to the Reorganized
Debtor
Totally agree with you declaes, just looking for the worst case scenario. You can always adjust numbers upward if you have some kind of a base.
Knowing when to exit a stock is as key as knowing when to enter. I screwed around with some numbers to see what kind of value BRTXQ will have once BRXT-100 is in use. Several obvious estimates are involved.
What is the value of BRTX's Patented Stem Cell Therapy?
(a) Back pain suffers in the U.S. total 31 million.
Estimated back pain suffers in Europe, 70 million. No direct link information was available on this. (b) Europe has 2.25 times the population of the U.S. (c) (d) They are also on median age 5 years older than the U.S. Population. This means a higher percentage of back problems as age equals health issues. Keeping the percentage equal with the U.S. Population, they would have 70 million suffering from lower back pain issues.
Total back pain sufferers in the U.S. and Europe, 100 million.
(estimate) 100 million back pain sufferers, divided by 40. The 40 represents the years 35-75 when most back problems are manifest, that equals about 2.5 million new back problems annually.
(estimate) Lets say 10% actually do something about their lower back problem. That equals 250,000 surgeries annually. Lets say they converted 25% of the surgeries to BRTX-100, that's 62,500 annually. (What would you rather have, general anesthesia, surgery and therapy, or local anesthetic and two injections with a needle? One would have to assume with a less expensive, less intrusive procedure, a larger percentage of patients would elect BRXT-100 for treatment)
(e) The average cost of a micro-discectomy is about $20,000 including therapy, medication and anesthetics. The average cost of a discectomy is up to $50,000, same costs included. Using the lower number as the cost for comparison.
(estimate) Let's use 50% of the cost of a discectomy or $10,000 per BRTX-100 procedure.
New technologies always have higher profit margins so lets have a 20% net income. $2,000.00 net per surgery.
62,500 annual surgeries x $10,000 = $625,000,000.00 gross annual income
62,500 annual surgeries x $2,000 = $125,000,000.00 net annual income
OS total including the 100 shares per dollar from the reorganization agreement: 3,018,987,105
$125,000,000.00 net income / OS 3,018,987,105 = .0414 per share
(f) Forward Price to earnings of 30.21
TOTAL VALUE .04 * 30 = $1.20 per share
SOURCES:
a) 31 million back pain sufferers in the U.S.:
https://www.statista.com/statistics/188871/adults-in-the-us-with-low-back-pain-by-region/
(b) Europe's Population:
https://worldpopulationreview.com/continents/europe-population
(c) U.S. Median Age:
https://www.worldatlas.com/articles/countries-with-the-highest-median-age.html#:~:text=Europe%20has%20a%20median%20age%20of%2042.7%20years,is%2051.4%20while%20the%20female%20is%2053.7%20years.
(d) Europe's Median Age
https://www.worldatlas.com/articles/countries-with-the-highest-median-age.html#:~:text=Europe%20has%20a%20median%20age%20of%2042.7%20years,is%2051.4%20while%20the%20female%20is%2053.7%20years.
(e) Cost of a Microdiscectomy around $20K
https://www.drkushwaha.com/education/much-back-surgery-cost/ NOTE: 2016 prices
(f) Bio-Technology Forward PE average
http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/pedata.html NOTE: 2020 PE values
U.S. Population:
https://worldpopulationreview.com/countries/united-states-population
Could you please post the proof that it isn't true? Thank you.
Doc didn't publish that LinkedIN PR. BioRemediesMD is responsible for it being issued.
Great post declaes!
Where do you think most of the $15 mil in debts came from? Funding. The largest funder, Auctus. Now they are in control of financial decisions made by BRTXQ.
You've enjoyed sowing FUD the last 5 days of the sell off phase after a huge run. We are now starting the ACCUMULATION phase which will work into another run up. Good luck to you.
So you're saying a technology that uses an individuals own stem cells to restore damaged spinal discs without surgery has no value. Lol, ok.
Are you in the back surgery sales industry per chance?
Lots of traders bought this at .0001-.0003. They rode it up into the .006-7 range and the real sharp traders sold.
It closed at .0045 the day of the last big runup and the next day, even more traders sold off, took their 10-20 bagger and moved on to other stocks.
The last of the sellers from the big move is now on in play. Todays trading is pretty much a standoff. It may move a bit up or down but the big swings are gone. There aren't a lot of big share dumps today.
This last bit of sellers may not know what the bankruptcy restructured contracts contain. Do they know the common shares are remaining in tact and a year of operational financing is in place? Do they know that additional financing can be sought if approved by AUCTUS?
This is reaching equilibrium where sellers versus buyers are dead even. We will trade in range for a bit. The smart early sellers are going to return along with others.
This will slowly start to creep up and then will run as the Q for bankruptcy is removed. Sellers here are selling at or near a bottom. Too bad for them.
715,412 shares at .0019
Nice catch, you're correct. Sorry.
There were a lot of shares turned in the last week. Anyone with a 10 or 20 bagger had to think of getting out with great profits.
Once we reach bottom, we churn in range for a bit IMO. As we get close to the creditors vote, we should start rising in anticipation of the Q getting removed.
It's getting to or is at the bottom. Here's the trading range for the last several days.
.0065 - .0033 a spread of .0032 on Tuesday
.0050 - .0027 a spread of .0023 on Wednesday
.0042 - .0028 a spread of .0014 on Thursday
.0029 - .0019 a spread of .0010 on Friday
.0026 - .0020 a spread of .006 so far Today
We haven't hit the low of Friday today. Its normal for the volume to slow as the spreads get closer.
The daily trading range
is rapidly narrowing.
Tuesday .0065 - .0033 .0032 spread
Wednesday .0050 - .0027 .0023
Thursday .0042 - .0028 .0014
Friday .0029 - .0019 .0010
Spot on, they put the big block in place until someone starts hitting and they take it up and away from Ask hits. When it slows, they drop the block back down. Clown games.
We're running right with the VWAP and MACD is really neutral, so it looks like fair market value. Yesterday we ran below all day. With the selling slowing down dramatically in this price range, we may move today.
If there is a unified mantra in penny stocks, its take the profit, never marry the stock.
I don't think this has been shorted, its just people taking their gains. Its a smaller volume day today and BRTXQ is a 10 or 20 bagger for many of the 1.6 billion shares and many look to lock up money. Smart and good for them.
It's going to take time to get all those sellers out of the way. Once they're gone, different story. Either way, good luck to you.
Turning White Fat Into Good Brown Fat (audio in link)
Not all fat is bad for you. Unlike white fat, which stores energy and unwanted pounds, brown fat dissipates that same energy into heat when we’re cold. Claudio Villanueva, Ph.D. assistant professor in biochemistry and investigator at the Center for Diabetes and Metabolism at the University of Utah, talks about his research investigating how to convert white fat into good, brown fat. Doing so could be the first step toward developing novel therapeutics to combat obesity.
https://healthcare.utah.edu/the-scope/shows.php?shows=0_ezizwc6d
Jul 20, 2015
Interview Transcript
Interviewer: Turning unwanted white fat into good fat. We'll talk about that research next on The Scope.
Announcer: Examining the latest research and telling you about the latest breakthroughs. The Science and Research Show is on The Scope.
Interviewer: I'm talking with Dr. Claudio Villanueva. He's assistant professor in the Department of Biochemistry and an investigator in the Center for Diabetes and Metabolism at the University of Utah. He was just awarded a grant from the National Institutes of Health to investigate fat biology with an eye towards developing innovative approaches to the obesity problem. Dr. Villanueva, your work is looking at differences between white fat and brown fat. I think a lot of people may not really know what brown fat is. Can you talk about that?
Dr. Villanueva: Sure. There are two different types of fat cells that are known as white and brown fat and the white fat is probably most known to people because the white fat cells can store lots of energy. When you consume excess calories that extra energy goes to your white fat cells and is stored at lipids. And over time these white fat cells increase in size and they also increase in number. They are the ones that you would sort of point to when you look at someone who is obese or overweight, they have lots of white fat. Brown fat on the other hand, its function is to generate heat to use that lipid and turn that chemical energy into heat. This process consumes a lot of energy.
Interviewer: So brown fat, is that something that you and I have normally?
Dr. Villanueva: Yes, adults have brown adipose tissue, some more than others. There is this correlation that obese individuals have less brown adipose tissue and individuals that are lean tend to have more. There's this correlation with obesity and diabetes as well where individuals that are protected against diabetes tend to have more brown fat.
Interviewer: So brown fat is kind of a good fat in a way.
Dr. Villanueva: That's right
Interviewer: Part of your project is to investigate how to convert white fat into brown fat, right? First of all why would you want to do that?
Dr. Villanueva: If we can turn on mechanisms that switches the balance from energy storage to energy expenditure this could be a therapeutic target to combat obesity. And there are these other types of fats cells called beige fat cells. They behave just like brown fat cells, they're thermogenic, they consume lots of energy, but typically they appear in the white adipose tissue or the white fat cells after prolonged cold exposure, so several days of cold exposure.
Interviewer: If your goal is to turn white fat cells into beige fat cells, I imagine first you need to do is understand what goes on within the cell in order to make that happen. What do we know about that, have you found out?
Dr. Villanueva: We've been interested in understanding how different types of fat cells are programmed and we found an auxiliary factor that works with a central transcription factor that makes all fat cells. And this auxiliary factor programs cells to become white fat cells. And it turns out that this auxiliary factor, if you inhibit it, if you knock it out in mice, or if you delete it in mice I should say, this results in a switch from storing energy to burning energy and this results in the appearance of more beige adipocytes.
So the way we're thinking about this is if we can find ways to inhibit this molecule, it's called TLA3, we might be able to shift the balance towards energy expenditure and have more beige adipocytes.
Interviewer: So where are you taking this research now?
Dr. Villanueva: We're trying to understand the molecular action between this auxiliary factor TLA3 and another factor called PRDM16. PRDM16 is important in making brown fat cells and we have some evidence that TLA3 is able to inhibit the activity of PRDM16. These auxiliary factors are talking to one other in a sense. Understanding how this crosstalk is occurring, we may be able to identify ways of inhibiting that negative interaction between TLA3 AND PRDM16. And to do that we really need to understand how this molecular interaction occurs.
We've also identified a new player that may be able to disrupt this interaction in cells and this factor is called AES and it's induced with prolonged cold exposure in rodents during the time when these beige adipocytes appear. What we think might be happening is that AES is turned on to prevent interaction between these two auxiliary factors and allow the activation of the beige program.
Interviewer: So what have you seen in mice so far? What kind of manipulations have you done and which ones sort of makes the biggest impact?
Dr. Villanueva: One of the impacts that we've seen so far is that in mice that lack TLA3 and adipose tissue, we see pockets of these beige adipocytes. And so now what we're doing is studying the physiological consequence of that. We know that beige adipocytes consume glucose and lipids and so if they consume glucose, we might be able to see effects on glucose metabolism which has implications for diabetes. One of the findings that we've had is that these knockout mice have improvements in glucose when we challenge them with prolonged cold exposure.
Interviewer: The ultimate goal is to get I would imagine, the best conversion from white fat to beige fat.
Dr. Villanueva: As far as developing therapeutics, the way that we're thinking about it is that it's oftentimes easier to make a drug that will be able to inhibit a pathway rather than activate it. So since we know that TLA3 is able to inhibit this beige program, the idea would be to inhibit the actions of TLA3. We're starting to develop assays to be able to do that and to search for drugs to disrupt this interaction.
So I think there are going to be two ways to do this effectively and one way is to reprogram the cells and the other way is to stimulate these cells. They need to be activated and so typically they're activated with cold or they can be activated with drugs that activate the Beta 3 adrenergic receptor. One way to do this is if you could find sort of common [inaudible 00:07:18] therapies that would reprogram cells and then also activate these cells then you would have highly active beige fat cells that are metabolizing glucose and metabolizing lipids. The average American puts on about a pound of fat, which is around 3500 calories.
Interviewer: A pound of fat per...?
Dr. Villanueva: Per year.
Interviewer: Per year.
Dr. Villanueva: A pound of fat doesn't sound like a lot in a year. And if you break down those 3500 calories over days it's about 10 calories a day that you're consuming in excess of what you're burning. And so if you can have small effects on energy expenditure which would consume those calories you might be able to prevent the average weight gain that most Americans have.
Announcer: Interesting, informative, and all in the name of better heath. This is the Scope Health Sciences Radio.
This is tight as a drum and ready to run. Its on high watch by a lot of players. Buys bring in more buys and it immediately runs. It consolidates and runs again. News will put this into the $4's very easily. Good luck to you!
LOL, don't hold back. Say what you really mean. Looks like it cleared out some challenged thinkers and its running a bit. Hope you're holding a bunch.
Nice call. This PR is screaming that BNGO is highly recognized throughout the genetics sector and they've got revenue coming up. Yet genius's are selling. Oh well.
The ability to scan any persons genome and locate their individual variants or genetic flaws is unbelievably huge. Treating a person with their unique code can save countless lives. They will be able to "illness proof" people in the near future because of the Saphyr system.
Some gene therapy firm going to pay big bucks to buy this company.
Looks like "they" got the shares they wanted at lowball prices. This should run soon.
Looks like a whale is getting into BNGO, taking out stops into the .70's and trying to scare holders out. This might have a nice run to it.
NNDM has consolidated that last move into the 2.40's for a couple of days. It's now thinning out resistance above and looks like it could move up again.